SCHEMBL6729656

SCHEMBL6729656

O=C(O)c1c[nH]c2ccc(OCCCc3ccccn3)nc12

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DHODH Q02127 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
NAAA Q02083 1/20 0.37
TET2 Q6N021 1/20 0.37
TET1 Q8NFU7 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6729649 0.86 HTR2C (0.47) HTR2CSMN1; SMN2
SCHEMBL6733358 0.78 PRKAB2 (0.37) CYP1A2CYP2C19DHODHTET2TET1
SCHEMBL6734102 0.77 PRKAG1 (0.46) CYP1A2CYP2C19MTNR1AMTNR1B
SCHEMBL6729681 0.77 PIM1 (0.43) CYP1A2CYP2C19SMN1; SMN2MTNR1AMTNR1B
SCHEMBL6724529 0.76 PIM1 (0.41) CYP1A2CYP2C19SMN1; SMN2MTNR1AMTNR1B
SCHEMBL6728722 0.76 MAPT (0.44) CYP1A2CYP2C19SMN1; SMN2GABRA1GABRB2
SCHEMBL6722084 0.75 PIM1 (0.48) CYP1A2CYP2C19SMN1; SMN2MTNR1AMTNR1B
SCHEMBL6726958 0.74 KDM4E (0.39) CYP1A2CYP2C19DHODHMTNR1AMTNR1B
SCHEMBL6722059 0.74 ALDH1A1 (0.43) CYP1A2CYP2C19SMN1; SMN2MTNR1AMTNR1B
SCHEMBL6726280 0.74 DHODH (0.46) CYP1A2SMN1; SMN2DHODHHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US claimed
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US disclosed